Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Florida and California represent equivalent areas of opportunity in the Alzheimer's disease drug market despite the large disparity in population size between the two states. Despite having a population half the size of California, Florida's more elderly-leaning population causes it to have almost the same number of Alzheimer's disease cases as the larger state (213,900 cases versus 263,900 cases, respectively).

"When we looked at other states such as New York and Texas, which have more residents than Florida, we found both to have fewer Alzheimer's patients because they have younger populations on average," stated Jason LaBonte, Ph.D., vice president of new product development at Decision Resources.

The new analytics tool entitled PatientFinder: Alzheimer's Disease estimates that, based on prescription volumes in both states, Florida's Alzheimer's population is undertreated versus California's, such that there are almost equal numbers of untreated Alzheimer's patients in each region (130,000 in California and 123,500 in Florida).

Why Pharmaceutical Companies Need this Information

With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.

About PatientFinder

PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:

  --  Disease-specific prevalence numbers for each U.S. state and MSA   --  Examination of treatment rates for the disease population to create       percent treated and percent untreated estimates by state and MSA   --  Unique analysis of the untreated population examined through a filter       of prescription (Rx) benefit coverage. The end result is an estimate       of how many patients are untreated but can afford therapy within each       territory--the true local measure of opportunity for pharmaceutical       companies    About Decision Resources 

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

      For more information, contact:         Natalia Morales                           Elizabeth Marshall       Decision Resources                        Decision Resources, Inc.       781-296-2691                              781-296-2563       nmorales@dresources.com                   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
nmorales@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008

View Now